Stay updated with breaking news from Lugano Classification. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Acalabrutinib plus bendamustine and rituximab (BR) led to a statistically significant improvement in PFS vs BR for treatment-naive mantle cell lymphoma.
Chidamide plus R-CHOP has received approval from China’s NMPA for the management of diffuse large B-cell lymphoma.
The FDA has lifted a partial clinical hold on a phase 1 trial evaluating NX-2127 in relapsed/refractory B-cell malignancies
Matching adjusted indirect comparison addresses key questions and limitations associated with previously presented analysis and suggests efficacy advantage of BRUKINSA vs acalabrutinib ...
-- Yescarta is the First and Only Treatment in Nearly 30 Years to Demonstrate Superior Overall Survival for Patients with Relapsed/Refractory Large B-cell Lymphoma Versus Standard of Care as...